# Safety and Efficacy of the GORE® Septal Occluder to Treat Ostium Secundum Atrial Septal Defects

Study · id `cardio:ct-nct01711983` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT01711983](<https://clinicaltrials.gov/study/NCT01711983>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT01711983

## In plain language

A trial with no phase registered on ClinicalTrials.gov. The registry status is completed. It enrolled 400 participants.

## Technical summary

Registry record NCT01711983. Allocation not applicable; no masking; primary purpose treatment. Start 2012-10 (actual); primary completion 2018-11-26 (actual). Results posted on 2020-08-21.

## Key facts

- Design: Interventional study; allocation not applicable; no masking; primary purpose treatment
- Phase: Not applicable
- Enrolled: 400 participants (enrolled count; ClinicalTrials.gov record NCT01711983, source copy `cardio:ctgov-nct01711983-2020-08-21`, retrieved 2026-10-26)
- Started: 2012-10 (actual) (ClinicalTrials.gov record NCT01711983, source copy `cardio:ctgov-nct01711983-2020-08-21`, retrieved 2026-10-26)
- Primary completion: 2018-11-26 (actual) (ClinicalTrials.gov record NCT01711983, source copy `cardio:ctgov-nct01711983-2020-08-21`, retrieved 2026-10-26)
- Completion: 2018-11-26 (actual) (ClinicalTrials.gov record NCT01711983, source copy `cardio:ctgov-nct01711983-2020-08-21`, retrieved 2026-10-26)
- Results first posted: 2020-08-21 (ClinicalTrials.gov record NCT01711983, source copy `cardio:ctgov-nct01711983-2020-08-21`, retrieved 2026-10-26)
- Countries: United States (ClinicalTrials.gov record NCT01711983, source copy `cardio:ctgov-nct01711983-2020-08-21`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct01711983-2020-08-21`, retrieved 2026-10-26)

## The registry's words

- Brief title: Safety and Efficacy of the GORE® Septal Occluder to Treat Ostium Secundum Atrial Septal Defects
- Condition: Septal Defect, Atrial
- Intervention (Device): GORE® CARDIOFORM Septal Occluder
- Lead sponsor: W.L.Gore & Associates
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Congenital heart disease (`core:congenital-heart-disease`)
- Registry lists this organization as the lead sponsor: W.L.Gore & Associates (`cardio:org-w-l-gore-associates`)

## Provenance

Content hash: 7fed58190e919c9ef55669e163666dba88a65316c37ba92a4f5f7a44bff87e4e
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
